Inhibitor Therapeutics, Inc.
INTI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for INTI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INTI
Inhibitor Therapeutics, Inc. (INTI) is a pharmaceutical development company focused on developing and commercializing innovative therapeutics based on already approved active pharmaceuticals with patent-protected methods of use or delivery, currently advancing a new formulation of itraconazole toward an NDA submission.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Inhibitor Therapeutics, Inc..
Inhibitor Therapeutics, Inc. (INTI) is a pharmaceutical development company focused on developing and commercializing innovative therapeutics based on already approved active pharmaceuticals with patent-protected methods of use or delivery, currently advancing a new formulation of itraconazole toward an NDA submission.
- Pharmaceutical development company focused on already approved active pharmaceuticals with patent-protected methods of use or delivery [sec_mda · as of 2026-08-14].
- Cash and equivalents of $0.5M as of 2026-06-30 [sec].
- Net income of -$0.6M for the period ended 2026-06-30 [sec].
- Shareholders' equity of -$1.3M as of 2026-06-30 [sec].
- Zero total debt as of 2026-06-30 [sec].
What works
- The company is developing a new formulation of itraconazole, an already approved active pharmaceutical, which may allow for a streamlined NDA submission without additional clinical trials if the FDA agrees [sec_mda · as of 2025-11-13].
- The company has no debt, reducing financial leverage risk [sec].
- The company has a clear regulatory pathway strategy: using a crossover PK study to demonstrate comparable levels of itraconazole to a prior FDA-approved formulation [sec_mda · as of 2025-11-13].
What to weigh
- Cash and equivalents have declined significantly from $7.7M (March 2024) to $0.5M (June 2026), indicating a rapid cash burn rate [sec_mda · as of 2024-05-13] [sec].
- Shareholders' equity is negative (-$1.3M as of 2026-06-30), suggesting accumulated losses exceed assets [sec].
- The company's ability to continue operations is uncertain given the low cash balance and ongoing net losses [sec].
- The FDA has not yet concluded whether additional clinical trials are required before NDA submission, creating regulatory uncertainty [sec_mda · as of 2025-05-14].
From the filings
Quoted directly from source documents.
The company's strategy involves using a new formulation of itraconazole and a crossover PK study to justify NDA submission without additional clinical trials.
“Utilizing the new formulation of itraconazole as the API (Active Pharmaceutical Ingredient) which has been developed with Avior, coupled with a crossover PK study to demonstrate that our formulation of itraconazole delivers comparable levels of itraconazole as the itraconazole formulation used in prior clinical trials, and approved by the FDA, we intend to obtain justification for the submission of an NDA without requiring additional clinical trials.”
SEC MD&A · November 13, 2025
Cash on hand was approximately $4.3 million as of March 31, 2025.
“Our current cash on hand, approximately $4.3 million as of March 31, 2025, is sufficient to continue to execute our busines”
SEC MD&A · May 14, 2025
The company expects to progress with the FDA to determine if additional clinical trials are needed before NDA submission.
“We expect to progress with the FDA to reach a conclusion on whether any additional clinical trials are required before submitting our New Drug Application (NDA).”
SEC MD&A · May 14, 2025
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — Cash of only $0.5M as of 2026-06-30 may be insufficient to fund operations without additional financing [sec].
- Negative shareholders' equity — Shareholders' equity of -$1.3M as of 2026-06-30 indicates accumulated losses exceed assets [sec].
- FDA regulatory uncertainty — FDA has not yet decided if additional clinical trials are needed before NDA submission, which could delay or increase costs [sec_mda · as of 2025-05-14].
- Dependence on single product — The company's pipeline is focused on a single itraconazole formulation, with no diversified product portfolio [sec_mda · as of 2025-11-13].
What to watch
- FDA decision on whether additional clinical trials are required before NDA submission [sec_mda · as of 2025-05-14].
- Company's ability to secure additional financing given low cash balance [sec].
- Progress of the crossover PK study for the new itraconazole formulation [sec_mda · as of 2025-11-13].
- Any updates on cash runway or operational plans in future SEC filings [sec_mda · as of 2026-08-14].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Inhibitor Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Inhibitor Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
2.1 months
OCF -$775K · Net income -$614K
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 0.4%
- Days to cover
- 0.1
- Shares short
- 19,880
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INTI short interestFrequently asked questions
What is the AI investment thesis for Inhibitor Therapeutics, Inc.?
Inhibitor Therapeutics, Inc. (INTI) is a pharmaceutical development company focused on developing and commercializing innovative therapeutics based on already approved active pharmaceuticals with patent-protected methods of use or delivery, currently advancing a new formulation of itraconazole toward an NDA submission.
What is Inhibitor Therapeutics, Inc.'s lead drug candidate?
Inhibitor Therapeutics, Inc.'s most advanced tracked candidate is suba-itraconazole (Preclinical) for Lung cancer.
Who is the CEO of Inhibitor Therapeutics, Inc.?
Dr. Francis E. O'Donnell Jr., M.D. is the chief executive officer of Inhibitor Therapeutics, Inc. (INTI).
Where is Inhibitor Therapeutics, Inc. headquartered?
Inhibitor Therapeutics, Inc. (INTI) is headquartered in Tampa, FL, United States.
What therapeutic areas does Inhibitor Therapeutics, Inc. focus on?
Inhibitor Therapeutics, Inc. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.